Theratechnologies presents two posters for treatment of HIV

Theratechnologies (THTX) announced two poster presentations at the 19th Annual American Conference for the Treatment of HIV, taking place May 1-3 in Chicago, Ill. Both presentations focus on issues surrounding excess visceral abdominal fat, a common comorbidity in people with HIV. One poster presents a new analysis of data from the Visceral Adiposity Measurement and Observations Study, in which EVAF was associated with reduced muscle quality in aging PWH. In the latest analysis from the multicenter VAMOS study, researchers investigated how EVAF, compared to subcutaneous fat, is associated with muscle quality in PWH on modern anti-retroviral regimens, and explored potential drivers of this relationship. Among the 170 participants, EVAF prevalence was 58%. Muscle quality was found to be lower with increasing age of participants, but was not significantly correlated with body mass index. EVAF was associated with lower skeletal muscle quality, as demonstrated by lower muscle mean attenuation. In the case series, investigators reported on the real-world use of tesamorelin for the treatment of EVAF in PWH, in combination with GLP-1 RAs, which are commonly used for diabetes and obesity management in the general population. Among the seven PWH evaluated in the case series, tesamorelin was initiated first in all cases to address EVAF, with a mean reduction in waist circumference of 1.3 inches. The principal reasons for adding a GLP-1-RA included improving BMI and diabetic control.